Ashish Gupta, MD
Cardiovascular Disease · Winter Park, FLNPI 1265521470
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $268,638 of the $317,393 with a category attached, or 84.6%. Johnson & Johnson accounts for 64.0% of it on its own, with 52 other manufacturers making up the rest. Reporting peaked in 2019 at $124,621 and has fallen 97.8% since, to $2,797 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 834 payments — averaging $380.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$203K
- Boehringer Ingelheim$62K
- Lilly USA, LLC$9K
- Scpharmaceuticals Inc.$9K
- Cook Medical LLC$6K
- Philips North America LLC$6K
- plus $22K from 47 others
Across 99 payments — averaging $1637.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$47K
- AstraZeneca$38K
- Endologix LLC$37K
- Sanofi US Services Inc.$13K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
- Boehringer Ingelheim Pharma GmbH & Co.kg$6K
- plus $12K from 4 others
What the payments were for
- Consulting fees$4,7501%
- Speaking & faculty fees$268,63885%
- Travel & lodging$15,6845%
- Food & beverage$28,1669%
- Education$1560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$200,634
- JARDIANCE$70,094
- FUROSCIX$8,646
- Zilver PTX$3,935
- Peripheral Orbital Atherectomy System$2,798
- (6554) Periph Vasc Undiv$1,600
- (9520) IGT Devices Undivided$1,541
- Indigo$1,331
- (6554) Peripheral Vascular Undivided$1,078
- Barostim Neo System$883
- VenaSeal$853
- RotarexS 6 F x 135 cm$741
- OPTIMIZER$627
- Impella$542
- UPTRAVI$529
- OPSUMIT$529
- VERQUVO$438
- Venclose Maven Catheter$429
- Repatha$353
- Ozempic$341
How this compares
$317,393 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 274 | $218,909 |
| EliquisApixaban | 136 | $103,412 |
| MounjaroTirzepatide | 71 | $73,138 |
| EntrestoSacubitril/Valsartan | 81 | $65,206 |
| JardianceEmpagliflozin | 82 | $59,932 |
| OzempicSemaglutide | 64 | $59,131 |
| Repatha SureclickEvolocumab | 75 | $51,301 |
| FarxigaDapagliflozin Propanediol | 76 | $45,114 |
| VascepaIcosapent Ethyl | 34 | $16,571 |
| Ranolazine ErRanolazine | 36 | $3,280 |
| ClopidogrelClopidogrel Bisulfate | 168 | $2,027 |
| Metoprolol Succinate | 149 | $1,992 |
| Losartan Potassium | 198 | $1,883 |
| Bumetanide | 40 | $1,726 |
| Cilostazol | 93 | $1,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $203,136 | $218,909274 claims |
| PfizerEliquis | $219 | $103,412136 claims |
| Lilly USA, LLCMounjaro | $9,348 | $73,13871 claims |
| NovartisEntresto | $1,043 | $65,20681 claims |
| Boehringer IngelheimJardiance | $61,650 | $59,93282 claims |
| Novo NordiskOzempic | $528 | $59,13164 claims |
| AstraZenecaFarxiga | $255 | $45,11476 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Winter Park
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.